Document is current

Article History

Received: 15 December 2025

Revised: 25 March 2026

Accepted: 20 May 2026

First Online: 10 June 2026

Compliance with ethical standards

:

: The scientific guarantor of this publication is Prof. Dr. Mireille Broeders.

: The authors of this manuscript declare relationships with the following companies: Bayer, Hologic, Siemens Healthineers, Screenpoint Medical, Sectra Benelux, Hologic, Volpara Solutions, Lunit, and iCAD. C.H.v.G. is the principal investigator of the DENSE trial, financially supported by the University Medical Center Utrecht (UMC Utrecht, UMCU DENSE), the Netherlands Organization for Health Research and Development (ZonMw ZONMW-200320002-UMCU, ZonMW Preventie 50–53125–98–014), KWF Kankerbestrijding (DCS-UU-2009–4348, UU-2014–6859, UU-2014–7151), the Dutch Pink Ribbon/A Sister’s Hope (Pink Ribbon-10074), Bayer AG Pharmaceuticals, Radiology (project number: BSP-DENSE), and Stichting Kankerpreventie Midden-West. C.H.v.G. is also the principal investigator of the DENSE-2 trial, financially supported by the Dutch Organisation for Knowledge and Innovation in Health, Healthcare and Well-being (ZonMw) (project number: 05550412310002), Bayer, Hologic, and Siemens Healthineers. C.H.v.G. is the director of the Dutch Cancer Society. M.J.M.B. received grants or has grants pending to the institution from ScreenPoint Medical, Sectra Benelux, Hologic, Volpara Solutions, Lunit, and iCAD. M.J.M.B. received speaker fees and travel support from Hologic and Siemens Healthcare.

: All authors have significant statistical expertise.

: Written informed consent was obtained from all subjects (patients) in this study.

: Institutional Review Board approval was obtained. All scientific content, data interpretation, and conclusions were developed and verified solely by the authors.

: Not applicable.

: